Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors

This article was originally published in PharmAsia News

Executive Summary

China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas

You may also be interested in...

WuXi Forms JV With PRA To Expand Clinical Services In China

WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.

Charles River Strikes Back In China With Research Models Business

After reassessing its China strategy, Charles River makes a new push by acquiring Vital River, the largest supplier of laboratory animals in China.

Mindray And WuXi PharmaTech’s Growth Strategy In 2Q: China Earnings Roundup (Part 1)

PharmAsia News takes a closer look at how Chinese healthcare companies have fared against the backdrop of a global economic slowdown, starting with two of the country’s leading companies in their respective industries.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts